WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018028449) METHOD FOR PREDICTING EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/028449    International Application No.:    PCT/CN2017/095144
Publication Date: 15.02.2018 International Filing Date: 31.07.2017
IPC:
A61K 39/395 (2006.01), C07K 16/00 (2006.01), C07K 16/30 (2006.01), A61P 35/00 (2006.01)
Applicants: BEIGENE, LTD.; c/o Mourant Ozannes Corporate Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 (KY).
LUO, Lusong [CN/CN]; (CN) (SC only).
DAI, Chengliang [CN/CN]; (CN) (SC only).
SUN, Zhijian [CN/CN]; (CN) (SC only)
Inventors: LUO, Lusong; (CN).
DAI, Chengliang; (CN).
SUN, Zhijian; (CN)
Agent: WU, FENG & ZHANG CO.; Room 305, Tower B Beijing Aerospace CPMIEC Building Beijing 100080 (CN)
Priority Data:
PCT/CN2016/093917 08.08.2016 CN
Title (EN) METHOD FOR PREDICTING EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS
(FR) PROCÉDÉ DE PRÉDICTION DE L'EFFICACITÉ D'INHIBITEURS DU POINT DE CONTRÔLE IMMUNITAIRE CHEZ DES PATIENTS ATTEINTS D'UN CANCER
Abstract: front page image
(EN)Disclosed is a method for predicting clinical response of a cancer patient to treatment with an immune checkpoint inhibitor, or a combination of two or more thereof, or with a combination of an immune checkpoint inhibitor and other antitumor drugs, by introducing bispecific T cell engager (BiTE) into the platform of lymphocytes containing T cells in vitro.
(FR)L'invention concerne un procédé pour prédire la réponse clinique d'un patient atteint d'un cancer à un traitement avec un inhibiteur du point de contrôle immunitaire, ou une combinaison de deux ou plus de deux de ceux-ci, ou avec une combinaison d'un inhibiteur de point de contrôle immunitaire et d'autres médicaments anti-tumoraux, par introduction d'un activateur de lymphocytes T bispécifiques (BiTE) dans la plate-forme de lymphocytes contenant des lymphocytes T in vitro.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)